These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 10383155)

  • 1. Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models.
    Gasparri A; Moro M; Curnis F; Sacchi A; Pagano S; Veglia F; Casorati G; Siccardi AG; Dellabona P; Corti A
    Cancer Res; 1999 Jun; 59(12):2917-23. PubMed ID: 10383155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor alpha.
    Moro M; Pelagi M; Fulci G; Paganelli G; Dellabona P; Casorati G; Siccardi AG; Corti A
    Cancer Res; 1997 May; 57(10):1922-8. PubMed ID: 9157986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor targeting with biotinylated tumor necrosis factor alpha: structure-activity relationships and mechanism of action on avidin pretargeted tumor cells.
    Corti A; Gasparri A; Sacchi A; Curnis F; Sangregorio R; Colombo B; Siccardi AG; Magni F
    Cancer Res; 1998 Sep; 58(17):3866-72. PubMed ID: 9731496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mutated human tumor necrosis factor-alpha improves the therapeutic index in vitro and in vivo.
    Yan Z; Zhao N; Wang Z; Li B; Bao C; Shi J; Han W; Zhang Y
    Cytotherapy; 2006; 8(4):415-23. PubMed ID: 16923618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody fragments in tumor pretargeting. Evaluation of biotinylated Fab' colocalization with recombinant streptavidin and avidin.
    Wilbur DS; Hamlin DK; Vessella RL; Stray JE; Buhler KR; Stayton PS; Klumb LA; Pathare PM; Weerawarna SA
    Bioconjug Chem; 1996; 7(6):689-702. PubMed ID: 8950488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for improving the anti-neoplastic activity of TNF by tumor targeting.
    Corti A
    Methods Mol Med; 2004; 98():247-64. PubMed ID: 15064445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of tumor necrosis factor alpha conjugated with divinyl ether and maleic anhydride copolymer on solid tumors in mice.
    Kaneda Y; Yamamoto Y; Kamada H; Tsunoda S; Tsutsumi Y; Hirano T; Mayumi T
    Cancer Res; 1998 Jan; 58(2):290-5. PubMed ID: 9443407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).
    Curnis F; Sacchi A; Borgna L; Magni F; Gasparri A; Corti A
    Nat Biotechnol; 2000 Nov; 18(11):1185-90. PubMed ID: 11062439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus.
    Gnant MF; Berger AC; Huang J; Puhlmann M; Wu PC; Merino MJ; Bartlett DL; Alexander HR; Libutti SK
    Cancer Res; 1999 Sep; 59(18):4668-74. PubMed ID: 10493523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biotinylation sites of tumor necrosis factor-alpha determined by liquid chromatography-mass spectrometry.
    Magni F; Curnis F; Marazzini L; Colombo R; Sacchi A; Corti A; Kienle MG
    Anal Biochem; 2001 Nov; 298(2):181-8. PubMed ID: 11700972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration.
    Curnis F; Sacchi A; Corti A
    J Clin Invest; 2002 Aug; 110(4):475-82. PubMed ID: 12189241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation.
    Tsutsumi Y; Kihira T; Tsunoda S; Kamada H; Nakagawa S; Kaneda Y; Kanamori T; Mayumi T
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1006-11. PubMed ID: 8819479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
    Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
    J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
    Bellnier DA; Gollnick SO; Camacho SH; Greco WR; Cheney RT
    Cancer Res; 2003 Nov; 63(22):7584-90. PubMed ID: 14633671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretargeted radioimmunotherapy of cancer: progress step by step.
    Boerman OC; van Schaijk FG; Oyen WJ; Corstens FH
    J Nucl Med; 2003 Mar; 44(3):400-11. PubMed ID: 12621007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor.
    Creasey AA; Reynolds MT; Laird W
    Cancer Res; 1986 Nov; 46(11):5687-90. PubMed ID: 3756916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effect of systemic administration of novel recombinant tumor necrosis factor (rTNF-S) with less toxicity than conventional rTNF-alpha in vivo.
    Gatanaga T; Noguchi K; Tanabe Y; Inagawa H; Soma G; Mizuno D
    J Biol Response Mod; 1989 Jun; 8(3):278-86. PubMed ID: 2746298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging.
    Guttinger M; Guidi F; Chinol M; Reali E; Veglia F; Viale G; Paganelli G; Corti A; Siccardi AG
    Cancer Res; 2000 Aug; 60(15):4211-5. PubMed ID: 10945632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
    van Schaijk FG; Oosterwijk E; Molkenboer-Kuenen JD; Soede AC; McBride BJ; Goldenberg DM; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2005 Mar; 46(3):495-501. PubMed ID: 15750164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.